Mitchell Elliott, MD
he/him/his
InstructorDownloadHi-Res Photo
About
Copy Link
Titles
Instructor
Departments & Organizations
- Center for Breast Cancer
- Early Phase Clinical Trial Program
- Yale Medicine
Education & Training
- Fellowship
- Princess Margaret Cancer Centre (2026)
- Fellowship
- University of Toronto (2024)
- Residency
- University of Toronto (2022)
- MD
- University of Toronto (2019)
- BS
- University of Windsor (2015)
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2024
Medical Oncology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2024
Internal Medicine
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2023
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Circulating Tumor DNA; Drug Development; Drug Resistance; Xenograft Model Antitumor Assays
ORCID
0000-0001-6711-7287
Research at a Glance
Publications Timeline
A big-picture view of Mitchell Elliott's research output by year.
Research Interests
Research topics Mitchell Elliott is interested in exploring.
30Publications
508Citations
Circulating Tumor DNA
Publications
Featured Publications
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
Elliott M, Howarth K, Main S, Antrás J, Echelard P, Dou A, Amir E, Nadler M, Shah E, Yu C, Bratman S, Bird T, Roh J, de Bruin E, Rushton C, Chen Y, Gladchuk S, George A, Birkeälv S, Alcaide M, Oton L, Putcha G, Woodhouse S, Bedard P, Siu L, Berman H, Cescon D. Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer. Clinical Cancer Research 2025, 31: 1520-1532. PMID: 39785866, PMCID: PMC11994999, DOI: 10.1158/1078-0432.ccr-24-3472.Peer-Reviewed Original ResearchCitationsAltmetricCirculating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.
Main S, Elliott M, Singhawansa A, Zou J, Zeng Y, Cheng N, Yu C, Hilton J, Awadalla P, He H, Bedard P, Lupien M, Bratman S, Cescon D. Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer. Cancer Research 2026 PMID: 42268298, DOI: 10.1158/0008-5472.can-26-0076.Peer-Reviewed Original ResearchAltmetricConceptsManagement of metastatic breast cancerCell-free DNATumor fractionEstrogen receptorBreast cancerCell-free methylated DNA immunoprecipitationBone-only diseaseLow tumor fractionAdvanced breast cancerMetastatic breast cancerTriple-negative BCBC detectionExternal test cohortStatus classificationDNA immunoprecipitationCfMeDIP-seqPlasma methylomesImmunohistochemical subtypesMetastatic settingBiological insightsHER2+Methylation signaturesMetastatic heterogeneityTumor phenotypeSignature regionsMethylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
Elliott M, Fuentes-Antrás J, Main S, Dou A, Shah E, Weipert C, Yalamanchili G, Bird T, Roh J, Yu C, Nadler M, Amir E, Berman H, Siu L, Bedard P, Cescon D. Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy. Nature Communications 2026 PMID: 42243127, DOI: 10.1038/s41467-026-73126-9.Peer-Reviewed Original ResearchAltmetricConceptsCirculating tumor DNAMetastatic breast cancerBreast cancerTreatment discontinuationHER2-negative metastatic breast cancerBaseline circulating tumour DNATime to treatment discontinuationMolecular progressionCDK4/6 inhibitor therapyEstrogen receptor-positiveClinical validationCtDNA monitoringRadiographic responseReceptor-positiveEndocrine therapyInhibitor therapyTumor DNACDK4/6 inhibitorsClinical outcomesTumor fractionTreatment strategiesTreatment monitoringCancerCDK4/6TherapyLongitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer
Pretz C, Fuentes-Antrás J, Main S, Dou A, Shah E, Van de Laar E, Weipert CM, Lin B, Das A, Amir E, Nadler MB, Yu C, Berman HK, Siu LL, Bedard PL, Elliott MJ, Cescon DW. Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer. Npj Precision Oncology 2026 DOI: 10.1038/s41698-026-01498-8.Peer-Reviewed Original Research
2026
Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma.
Park C, Demicco E, Howarth K, Elliott M, Chung P, Birkeälv S, Alcaide M, Lee J, Segui N, Arones L, Phillips M, Hafstad V, Ferguson P, Wunder J, Shultz D, Salawu A, Abdul Razak A. Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma. Clinical Cancer Research 2026, of1-of9. PMID: 42240449, DOI: 10.1158/1078-0432.ccr-26-0323.Peer-Reviewed Original ResearchAltmetricConceptsLocalized soft tissue sarcomaCirculating tumor DNASoft tissue sarcomasAdjuvant systemic therapySystemic therapyTissue sarcomasFollow-upHigh-risk soft tissue sarcomasPostoperative windowCirculating tumor DNA dynamicsAssociated with early recurrenceMedian clinical follow-upDetect circulating tumor DNACirculating tumor DNA concentrationsCirculating tumor DNA detectionMolecular residual diseaseClinical follow-upPreoperative radiationRadiological responseResidual diseaseMetastatic diseaseMetastatic recurrenceEarly recurrenceTumor DNARadiological surveillanceLongitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer
Pretz C, Fuentes-Antrás J, Main S, Dou A, Shah E, Van de Laar E, Weipert C, Lin B, Das A, Amir E, Nadler M, Yu C, Berman H, Siu L, Bedard P, Elliott M, Cescon D. Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer. Npj Precision Oncology 2026 PMID: 42236890, DOI: 10.1038/s41698-026-01498-8.Peer-Reviewed Original ResearchAltmetricConceptsTime to treatment discontinuationMetastatic breast cancerCirculating tumor DNAOverall survivalTumor fractionBreast cancerLiquid biopsyCtDNA kineticsMetastatic breast cancer managementChanges to clinical outcomesPersonalized clinical decision-makingSerial liquid biopsiesCox proportional hazards modelsProportional hazards modelEndocrine therapyTreatment discontinuationCDK4/6 inhibitorsTumor DNAClinical outcomesClinical decision-makingHazards modelPatient-specificBiopsyLongitudinal evaluationPatientsPan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay
Strum S, Murray C, Genta S, Sanz-Garcia E, Razak A, Lheureux S, Pipinikas C, Wang B, Chevalier A, Smith C, Spreafico A, Siu L, Elliott M, Cescon D. Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay. International Journal Of Molecular Sciences 2026, 27: 3979. PMID: 42123559, PMCID: PMC13164046, DOI: 10.3390/ijms27093979.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsCirculating tumor DNAHigh-grade serous ovarian cancerTumor typesCtDNA detectionRecurrent high-grade serous ovarian cancerCirculating tumour DNA measurementsPositive ctDNAStage IV melanoma patientsCirculating tumor DNA detectionStage II-IV cancerCancer typesIV melanoma patientsTreatment response assessmentSerous ovarian cancerPan-cancer cohortManagement of cancerVariant allele fractionCtDNA assaysMelanoma patientsCtDNA analysisOvarian cancerTumor DNADetection rateUniversity Health NetworkClinical characteristics
2025
Circulating tumor DNA as a biomarker in early phase clinical trials
Tan H, Elliott M, Silverman I, Siu L, Yap T. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell 2025, 44: 240-247. PMID: 41418771, DOI: 10.1016/j.ccell.2025.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricA retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
Makarem M, Hoang T, Elliott M, Rabinovitch A, Hueniken K, Kuang S, Schmid S, Tsao M, McGaha T, Ohashi P, Shepherd F, Bradbury P, Liu G, Leighl N, Sacher A, Lau S. A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases. Therapeutic Advances In Medical Oncology 2025, 17: 17588359251367315. PMID: 41164205, PMCID: PMC12559634, DOI: 10.1177/17588359251367315.Peer-Reviewed Original ResearchAltmetricPersonalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy
Fuentes-Antrás J, Elliott M, Main S, Echelard P, Dou A, Bedard P, Amir E, Nadler M, Meti N, Gregorio N, Shah E, Van de Laar E, Yu C, Deng Y, Gates L, Murray C, Smith C, Chevalier A, Bratman S, Siu L, Berman H, Cescon D. Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy. Npj Breast Cancer 2025, 11: 74. PMID: 40683861, PMCID: PMC12276344, DOI: 10.1038/s41523-025-00783-2.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity Critical Reviews in Oncology/Hematology
04/01/2024 - PresentJournal ServiceEditorial Board Memberactivity Cancer Research Communications
04/01/2026 - PresentJournal ServiceEditorial Board Member
Honors
honor Margaret Foti Foundation Scholar-in-Training Award
12/09/2025National AwardAmerican Association for Cancer Researchhonor Pfizer Graduate Scholarship-Clinician Scientist Scholarship
01/01/2025International AwardPfizer CanadaDetailsCanadahonor Novartis Oncology Young Canadian Investigator Award (NOYCIA)
06/02/2024International AwardNovartis Canadahonor Conquer Cancer Syndax Pharmaceuticals, Inc. Endowed Merit Award
06/02/2024National AwardAmerican Society of Clinical Oncology
Get In Touch
Copy Link
Contacts
Mailing Address
Yale Cancer Center
300 George St
New Haven, CONNECTICUT 06511-6624
United States